SUBSTANTIAL SHAREHOLDERS

So far as is known to our Directors, immediately after the [**REDACTED**], assuming the [**REDACTED**] is not exercised, the following persons are expected to have an interest and/or short positions in our Shares or underlying Shares of our Company which would fall to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company.

		Immediately preceding completion of the Share Subdivision and [REDACTED]		Immediately after the Share Subdivision and the [REDACTED] (assuming the [REDACTED] is not exercised)	
Name	**Nature of interest**[(1)]	**Number of Shares**	**Approximate percentage of interest in our Company**	**Number of Shares**	**Approximate percentage of interest in our Company**
Dr. Tan	Founder of a discretionary trust[(2)]	746,957	2.83%	3,734,785	[**REDACTED**]
	Trustee[(2)]	746,957	2.83%	3,734,785	[**REDACTED**]
	Interest in controlled corporation[(2)]	1,861,441	7.06%	9,307,205	[**REDACTED**]
	Interest of a party to an agreement[(3)]	2,513,625	9.54%	12,571,790	[**REDACTED**]
JinsTan Holdings Limited	Beneficial owner[(2)]	1,861,441	7.06%	9,307,205	[**REDACTED**]
Ms. Jin	Founder of a discretionary trust[(2)]	746,957	2.83%	3,734,785	[**REDACTED**]
	Trustee[(2)]	746,957	2.83%	3,734,785	[**REDACTED**]
	Spouse interest[(2)(3)]	4,375,066	16.60%	21,878,995	[**REDACTED**]
Dr. Chen	Spouse interest[(4)]	2,513,625	9.54%	12,571,790	[**REDACTED**]
	Interest of a party to an agreement[(3)]	3,355,355	12.73%	16,776,775	[**REDACTED**]
Ms. Li	Interest in controlled corporation[(4)]	2,513,625	9.54%	12,571,790	[**REDACTED**]
	Interest of a party to an agreement[(3)]	3,355,355	12.73%	16,776,775	[**REDACTED**]
Mr. XU Yonghong	Interest in controlled corporation[(5)]	4,256,239	16.15%	21,752,145	[**REDACTED**]
Hangzhou Kaitai Capital	Interest in controlled corporation[(5)]	2,515,751	9.55%	12,578,755	[**REDACTED**]
Shanghai Kaitai	Beneficial owner[(5)]	1,882,704	7.14%	9,413,520	[**REDACTED**]
Temasek Holdings (Private) Limited	Interest in controlled corporation[(6)]	3,077,293	11.68%	16,705,125	[**REDACTED**]
Elbrus Investments Pte. Ltd.	Beneficial owner[(6)]	1,868,989	7.09%	10,569,415	[**REDACTED**]
Dr. SHI Yi	Interest in controlled corporation[(7)]	2,378,732	9.03%	12,207,625	[**REDACTED**]
LAV Biosciences Fund V, L.P.	Beneficial owner[(7)]	1,911,200	7.25%	9,869,965	[**REDACTED**]
OrbiMed Asia Partners V, L.P.	Beneficial owner[(8)]	1,870,130	7.10%	9,350,650	[**REDACTED**]

Notes:

(1) All interests stated are long positions.

(2) Minsion LLC is an investment holding company incorporated in the state of Delaware, the U.S. As of the Latest Practicable Date, the entire share capital of Minsion LLC was wholly owned by Ms. Jin in her capacity as the trustee of a discretionary family trust settled by Dr. Tan for the benefit of his family. Dr. Tan was the investment trustee of the trust and therefore solely controlled the voting rights attaching to the Shares held by Minsion LLC pursuant to the trust deed. Therefore, upon [**REDACTED**], each of Dr. Tan (as the settlor and investment trustee) and Ms. Jin (as the trustee) is taken to be interested in the 3,734,785 Shares held by Minsion LLC under the SFO.

Minyoung LLC is an investment holding company incorporated in the state of Delaware, the U.S. As of the Latest Practicable Date, the entire share capital of Minyoung LLC was wholly owned by Dr. Tan in his capacity as the trustee of a discretionary family trust settled by Ms. Jin for the benefit of her family. Dr. Tan as the trustee of the trust solely controlled the voting rights attaching to the Shares held by Minyoung LLC pursuant to the trust deed. Therefore, upon [**REDACTED**], Ms. Jin (as the settlor) and Dr. Tan (as the trustee) are taken to be interested in the 3,734,785 Shares held by Minyoung LLC under the SFO.

JinsTan Holdings Limited is a limited liability company incorporated in the BVI and was wholly owned by Dr. Tan as of the Latest Practicable Date. Therefore, upon [**REDACTED**], Dr. Tan is deemed to be interested in the 9,307,205 Shares held by JinsTan Holdings Limited under the SFO.

(3) As of the Latest Practicable Date, pursuant to the Concert Party Arrangements, Dr. Tan and Ms. Li agreed to act in concert by aligning the voting rights controlled by them at the Shareholders' meetings of the Company. Dr. Tan and Ms. Jin are spouse. Ms. Li and Dr. Chen are spouse. Therefore, Dr. Tan, Ms. Jin, Dr. Chen and Ms. Li are deemed to be jointly interested in the aggregate number of Shares held by each other under the SFO. For further details, see "History, Reorganization and Corporate Structure — Concert Party Arrangements."

(4) Vitalgene LLC is a limited liability company incorporated in the state of Delaware, the U.S. As of the Latest Practicable Date, the entire share capital of Vitalgene LLC was owned by the family trusts settled by Dr. Chen. These family trusts are directed trusts to which Ms. Li is the investment advisor directing trustee, The Bryn Mawr Trust Company of Delaware, of these trusts. Therefore, upon [**REDACTED**] Ms. Li (as the investment advisor) and The Bryn Mawr Trust Company of Delaware (as the trustee) is taken to be interested in the 8,967,585 Shares held by Vitalgene LLC under the SFO.

Amber Biopharma Science Holdings Limited ("**Amber Biopharma**") is a limited liability company incorporated in the BVI. As of the Latest Practicable Date, the entire share capital of Amber Biopharma was owned by Livemore Crystal LLC, which was in turn owned by the family trust settled by Ms. Li. The family trust is a directed trust to which Ms. Li is the investment advisor, directing the trustee, The Bryn Mawr Trust Company of Delaware. Therefore, upon [**REDACTED**] Ms. Li (as the settlor) and The Bryn Mawr Trust Company of Delaware (as the trustee) is taken to be interested in the 3,604,205 Shares held by Amber Biopharma under the SFO.

(5) As of the Latest Practicable Date, each of Shanghai Kaitai Chuangyu Management Consulting Limited Partnership ("**Shanghai Kaitai**"), Xiamen Jinyuan Kaitai Zhanhong Healthy Growth Venture Investment Partnership (Limited Partnership) ("**Xiamen Kaitai**") and Nanjing Chuangyi Kaitai Venture Capital Partnership (Limited Partnership) ("**Nanjing Kaitai**"), was controlled by Hangzhou Kaitai Capital Management Co., Ltd. ("**Hangzhou Kaitai Capital**"), which was controlled by XU Yonghong. Each of Kaitai HST Limited, Kaitai JY-II Limited, Kaitai HTY Limited and Kaitai ZS Limited was ultimately controlled by XU Yonghong.

Therefore, upon [**REDACTED**], XU Yonghong is deemed to be interested in the 21,752,145 Shares held by Shanghai Kaitai, Xiamen Kaitai, Nanjing Kaitai, Kaitai HST Limited, Kaitai JY-II Limited, Kaitai HTY Limited and Kaitai ZS Limited in aggregate under the SFO, and Hangzhou Kaitai Capital is deemed to be interested in the 12,578,755 Shares held by Shanghai Kaitai, Xiamen Kaitai and Nanjing Kaitai in aggregate under the SFO.

(6) As of the Latest Practicable Date, Elbrus Investments Pte. Ltd. was wholly owned by Temasek Life Sciences Private Limited, which was in turn wholly owned by Fullerton Management Pte Ltd, a company wholly owned by Temasek Holdings (Private) Limited. Therefore, upon [**REDACTED**], each of Temasek Life Sciences Private Limited, Fullerton Management Pte Ltd and Temasek Holdings (Private) Limited is deemed to be interested in the 10,569,415 Shares held by Elbrus Investments Pte. Ltd. under the SFO.

As of the Latest Practicable Date, each of True Light Investments P Pte. Ltd. and True Light Lifesciences VC B Pte. Ltd. was directly or indirectly wholly owned by the general partners ("**True Light GPs**") on behalf of funds managed by True Light Capital. Each of True Light GPs and True Light Capital is an independent, indirectly wholly-owned subsidiary of Temasek Holdings (Private) Limited. Therefore, upon [**REDACTED**], Temasek Holdings (Private) Limited is deemed to be interested in the 1,460,385 and 4,675,325 Shares held by True Light Investments P Pte. Ltd. and True Light Lifesciences VC B Pte. Ltd. under the SFO.

(7) As of the Latest Practicable Date, LAV Biosciences Fund V, L.P. was controlled by its general partner LAV GP V, L.P., whose general partner was LAV Corporate V GP, Ltd., a Cayman exempted company wholly owned by Dr. SHI Yi. Therefore, upon [**REDACTED**], each of LAV GP V, L.P., LAV Corporate V GP, Ltd. and Dr. SHI Yi is deemed to be interested in the 9,869,965 Shares held by LAV Biosciences Fund V, L.P under the SFO.

As of the Latest Practicable Date, LAV Fund VI, L.P. was controlled by its general partner LAV GP VI, L.P., which is in turn controlled by its general partner LAV Corporate VI GP, Ltd. LAV Fund VI Opportunities, L.P. was controlled by its general partner LAV GP VI Opportunities, L.P., which is in turn controlled by its general partner LAV Corporate VI GP Opportunities, Ltd. Each of LAV Corporate VI GP, Ltd. and LAV Corporate VI GP Opportunities, Ltd. is wholly owned by Dr. SHI Yi. Therefore, upon [**REDACTED**], Dr. SHI Yi is deemed to be interested in the 1,168,830 Shares and 1,168,830 Shares respectively held by LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P. under the SFO.

(8) As of the Latest Practicable Date, OrbiMed Asia Partners V, L.P. was wholly owned by OrbiMed Asia GP V, L.P., which was in turn wholly owned by OrbiMed Advisors V Limited. OrbiMed Advisors LLC is the advisory company of OAP V. OrbiMed Advisors LLC exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. Therefore, upon [**REDACTED**], each of OrbiMed Asia GP V, L.P., OrbiMed Advisors V Limited, OrbiMed Advisors LLC, Carl L. Gordon, Sven H. Borho, and W. Carter Neild is deemed to be interested in the 9,350,650 Shares held by OrbiMed Asia Partners V, L.P. under the SFO.

Except as disclosed above, our Directors are not aware of any persons who will, immediately following completion of the [**REDACTED**] (assuming that the [**REDACTED**] is not exercised), have any interests and/or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, is entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of any member of our Company.